论文部分内容阅读
目的探讨替吉奥联合吉西他滨同步放化疗治疗局部晚期胰腺癌的疗效和安全性。方法选择26例不可手术切除的局部晚期胰腺癌患者,随机分为替吉奥联合吉西他滨同步放化疗组(观察组,13例)和5氟尿嘧啶(5-FU)联合吉西他滨同步放化疗组(对照组,13例)。观察组给予替吉奥40mg/m2,bid,第1～18天;同时给予吉西他滨1000mg/m2第1天、第5天、第29天,应用6 MV直线加速器,接受总放疗剂量54 Gy、27次。对照组给予5-Fu 750mg/m2,第1～4天、第25～28天;吉西他滨的用法及放疗方法均同观察组。结果观察组总有效率为38.5%,1年生存率为53.8%,与对照组比较有生存优势。观察组不良反应较轻,患者耐受性更好,生活质量明显改善。结论替吉奥联合吉西他滨同步放疗治疗局部晚期胰腺癌患者临床疗效好,不良反应明显轻,患者耐受性良好。
Objective To investigate the efficacy and safety of tegaserod in combination with gemcitabine concurrent chemoradiotherapy in the treatment of locally advanced pancreatic cancer. Methods Twenty-six patients with unresectable locally advanced pancreatic cancer were randomly divided into two groups: the gemcitabine plus gemcitabine group (13 cases) and the 5-fluorouracil (5-FU) plus gemcitabine group (control group , 13 cases). The patients in the observation group were treated with tegaserod 40 mg / m2 bid twice daily for 1 to 18 days. At the same time gemcitabine 1000 mg / m2 was given on day 1, day 5 and day 29 with a 6 MV linear accelerator, Times. The control group was given 5-Fu 750mg / m2, the first to 4 days, 25 to 28 days; gemcitabine usage and radiotherapy methods were the same observation group. Results The observation group had a total effective rate of 38.5% and a one-year survival rate of 53.8%. Compared with the control group, the survival rate was superior. Adverse reactions in the observation group were lighter, patients were better tolerated and their quality of life improved significantly. Conclusion The combination of getigoc and gemcitabine for simultaneous treatment of locally advanced pancreatic cancer has good clinical efficacy, mild adverse reactions and good tolerability.